Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Tempest Therapeutics, Inc. | ovas-20150630x10q.htm |
| EX-31.2 - EXHIBIT 31.2 - Tempest Therapeutics, Inc. | ovas-20150630xex312.htm |
| EX-10.1 - EXHIBIT 10.1 - Tempest Therapeutics, Inc. | ovas-20150630xex101.htm |
| EX-32.1 - EXHIBIT 32.1 - Tempest Therapeutics, Inc. | ovas-20150630xex321.htm |
| EX-31.1 - EXHIBIT 31.1 - Tempest Therapeutics, Inc. | ovas-20150630xex311.htm |
EXHIBIT 32.2
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, by Chief Executive Officer
In connection with the Quarterly Report on Form 10-Q of OvaScience, Inc. (the “Company”) for the period ended June 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Jeffrey Young, as principal financial officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: | August 10, 2015 | |
/s/ Jeffrey Young | ||
Jeffrey Young | ||
Chief Financial Officer (Principal accounting and financial officer) | ||